Please login to the form below

Not currently logged in
Email:
Password:

drug launch

This page shows the latest drug launch news and features for those working in and with pharma, biotech and healthcare.

Teva names new CFO and bulks up its opioid liability fund

Teva names new CFO and bulks up its opioid liability fund

A new autoinjector formulation of the drug is due to launch in the coming months that could help accelerate growth. ... rheumatoid arthritis, Teva and Celltrion’s drug is expected to make quick headway in the market thanks to a 10% discount on

Latest news

  • Novo bolstered by new diabetes, obesity products Novo bolstered by new diabetes, obesity products

    Also helping to bolster its sales and growth is new oral semaglutide drug Rybelsus, which received approval from the FDA in the US  recently. ... In September, the Danish drug-maker said it will launch a cut-price version of its insulin drug NovoLog,

  • Amgen exits neuroscience R&D to focus on growth areas Amgen exits neuroscience R&D to focus on growth areas

    The unit scored a victory with the recent approval and launch of chronic migraine drug  Aimovig (erenumab), but earlier this year was forced to abandon its  umibecestat candidate for Alzheimer’s ... disease after trials suggested patients did worse

  • Acacia eyes February FDA verdict for refiled nausea drug Barhemsys Acacia eyes February FDA verdict for refiled nausea drug Barhemsys

    the contract manufacturing organisation making the active ingredient in the drug after an inspection. ... that the company’s “US sales team is positioning itself for a prompt launch”.

  • AbbVie scores FDA approval for arthritis treatment upadacitinib AbbVie scores FDA approval for arthritis treatment upadacitinib

    Humira has been hit hard by the recent launch of biosimilars, with the drug experiencing rapid losses in Europe. ... However, the pharma company does not see these side effects posing a risk to sales of the drug, with suggestions that the risks are

  • Chi-Med cues up two more regulatory filings in cancer Chi-Med cues up two more regulatory filings in cancer

    in the China National Reimbursement Drug List (NRDL) at the next update later this year. ... Within two years, To expects Chi-Med to become “a fully integrated and globally-facing biopharmaceutical company with capability to discover, develop and

More from news
Approximately 1 fully matching, plus 194 partially matching documents found.

Latest Intelligence

  • Cooking up a co-creation feast – beyond vanilla Cooking up a co-creation feast – beyond vanilla

    Another challenge for us as agencies is to nudge our clients to involve the end user earlier and earlier in the drug development process. ... Often, we co-design material to support the use of a drug during its clinical development.

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    This year’s report additionally features insight from the new Cortellis Analytics – Drug Timeline &Success Rates module, an analytic that predicts the probability of launch and timeline to market for ongoing ... The company expects to launch the drug

  • Launch trends 2019 Launch trends 2019

    What are the big trends in pharma and biotech drug launches for 2019? ... Large companies entering competitive spaces are planning for increased launch budgets to compete and win.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Camurus is currently preparing to launch the drug in the first European markets as early as January, and expects ‘substantial’ sales of the treatment during 2019, although it will take three ... Compared with a similar treatment marketed by Indivior,

  • A catalyst for change A catalyst for change

    This was considered a significant step in the internationalisation of the Chinese drug approval process. ... If any application is filed to launch a drug or medical device in China for the first time, the applicant shall provide clinical trial data on

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • NDA Group appoints Alison McGregor as its principal consultant NDA Group appoints Alison McGregor as its principal consultant

    She joins the group following a new US office launch. Drug development consultancy, NDA Group, has appointed Alison McGregor as its principal consultant following the opening of its new US office

  • Medicines Discovery Catapult appoints CEO Medicines Discovery Catapult appoints CEO

    Chris' experience of leading companies operating in life sciences combined with his in-depth knowledge of drug discovery will be of tremendous value to the company.”. ... The Catapult will engage the UK's experienced drug discovery talent and help

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).

  • Paolo Paoletti named as executive chairman of Kesios Paolo Paoletti named as executive chairman of Kesios

    Paoletti was formerly the first appointed president of GSK Oncology, where he was responsible for the overall oncology business within the firm and oversaw activities from early drug discovery through to ... clinical development, launch and life cycle

  • Purdue looks to Merck for new CEO Purdue looks to Merck for new CEO

    His previous roles include president of Merck US, during which time he helped to launch the hepatitis C drug Victrelis (boceprevir) and led the acquisition of ophthalmology company Inspire Pharmaceuticals.

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics